Abstract
33rd Annual Meeting & Pre-Conference Programs of the Society for Immunotherapy of Cancer (SITC 2018): Late-Breaking Abstracts
Highlights
Tumor mutational burden (TMB) is a measure of the number of somatic mutations and a predictive biomarker of response to immune checkpoint inhibitors (ICI) across several cancers
Panel-derived TMB strongly correlated with whole exome sequencing (WES)-derived TMB
As Imprime is known to complex with serum IgG Anti-beta glucan antibodies (ABA), a drop in the free ABA levels and a concomitant increase in the circulating immune complexes (CIC) was observed at the end of infusion (EOI) of every Imprime dose
Summary
Tumor mutational burden (TMB) is a measure of the number of somatic mutations and a predictive biomarker of response to immune checkpoint inhibitors (ICI) across several cancers. There were no treatment-related deaths.Translational data is being evaluated for alterations in MDSCs, interferon-gamma-induced proteins and proliferation of previously exhausted CD8 memory T-cells in blood, as well as changes in immune infiltrates from paired tumor biopsies Currently, translational data is available in the anti-PD1 therapy refractory melanoma patient showing an 86% reduction in MDSCs at C2D1 by flow cytometry and a 68% increase in the proliferative fraction of previously exhausted T-cells at C3D1 relative to baseline.Updated clinical and translational data from the combination expansion cohorts will be presented. We examined how well functional tumor-immune biology was preserved across the lymphoid and myeloid compartments during ex-vivo culture using multiple different platforms including cytokine multiplex analysis, flow cytometry, gene expression quantification and multispectral immunohistochemistry In this platform, we interrogated clinically-approved PD-1 inhibitors (e.g. Nivolumab and Pembrolizumab) using tumor biopsies from patients (N=50) with head and neck squamous cell carcinoma (HNSCC). Our study indicates the potential of PSI as an integral clinical biomarker for evaluating the efficacy of the therapy on a per-patient basis, and enables understanding of the checkpoint mechanism and its application to drug development
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
